GlassScriptPhysician profile
Tonia K Ackerman
NPI 1932142692
$17,333.48
in general payments reported to CMS, 2019-2025
26 companies · $11K in 2025
The $11K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,470 · 2022: $1,402 · 2023: $2,086 · 2024: $1,474 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,050 · Food and Beverage: $5,944 · Travel and Lodging: $1,707 · Education: $559 · Consulting Fee: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,050.00 |
| Food and Beverage | $5,944.31 |
| Travel and Lodging | $1,707.48 |
| Education | $559.32 |
| Consulting Fee | $200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $9,410.82 | 2021-2025 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $1,309.83 | 2021-2025 | Tremfya |
| Genzyme Corporation | $962.38 | 2021-2025 | |
| Ucb, INC. | $699.60 | 2021-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $694.33 | 2021-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $538.14 | 2022-2025 | Ilumya |
| Novartis Pharmaceuticals Corporation | $526.50 | 2023-2025 | |
| Galderma Laboratories, L.P. | $452.81 | 2021-2025 | Nemluvio |
| Incyte Corporation | $417.52 | 2021-2024 | Opzelura |
| Dermavant Sciences, INC. | $368.26 | 2023-2024 | Vtama |
| Lilly USA, LLC | $354.10 | 2023-2025 | Taltz, Ebglyss |
| Pfizer INC. | $256.78 | 2022-2025 | |
| Amgen INC. | $244.59 | 2022-2025 | Otezla, Otezla |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $209.00 | 2021-2024 | Arazlo, Jublia, Siliq |
| Leo Pharma INC. | $192.09 | 2022-2025 | Adbry |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $144.39 | 2021-2023 | |
| Regeneron Healthcare Solutions, INC. | $143.78 | 2021-2025 | Dupixent |
| Arcutis Biotherapeutics, INC. | $140.30 | 2023-2025 | Zoryve |
| Organon LLC | $50.87 | 2025 | Vtama |
| Vyne Pharmaceuticals INC. | $43.84 | 2021 | |
| Biofrontera INC. | $40.63 | 2021-2023 | Xepi, Bf-Rhodoled, Ameluz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.26 | 2023-2024 | Spevigo |
| Janssen Scientific Affairs, LLC | $31.82 | 2024 | Tremfya |
| Organogenesis INC. | $27.94 | 2025 | Affinity |
| Dermira, INC. | $21.40 | 2021 | |
| Botanix Sb INC | $18.50 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tonia Ackerman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.